Investors

Company:Stem Cell Innovations, Inc. (SCI)
Symbol:SCLL.OB
History:In February 2006, Stem Cell Innovations, Inc. (formerly known as Interferon Sciences, Inc.) acquired Amphioxus Cell Technologies, Inc. in a merger. Amphioxus Cell Technologies was founded in 1995 with a focus on drug discovery and toxicology testing. Amphioxus's cell biology capabilities were expanded with the acquisition from Plurion, Inc. of a license to patents and patent applications important for the development and use of human pluripotent stem cells.

Stem Cell Innovations, Inc.

11222 Richmond Ave., Suite 180
Houston, TX 77082-2646
USA
T: +1 281 679 7900

Corporate and Media Relations

Andrew Hellman
CEOcast, Inc.
369 Lexington Avenue - 4th Floor
New York, NY 10017
T: +1 212 732 4300

Corporate and Media Relations

Computershare Investor
Services, Inc.
250 Royall Street
Mail Stop 1A
Canton MA 02021
T: +1 312 360 5432


Current Press Releases

  • Oct 23, 2007
    Stem Cell Innovations Cites Two Recent Government Documents Supporting the use of Cell-Based Assays for Toxicity Testing
  • June 25, 2007
    Stem Cell Innovations and High Q Foundation Collaborate to Develop Novel Models of Huntington's Disease
  • May 30, 2007
    Stem Cell Innovations and TNO to Collaborate on Generating PluriCell Derived Cartilage and Cardiomyocytes; Awarded Dutch EZ-Cofinancing Grant
Read More


Upcoming Events

read more